Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Surbhi Warrior

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Hematology & Oncology|December 25, 2024
Current and future immunotherapy for breast cancerNatalie K Heater, Surbhi Warrior, Janice Lu
Cancers|June 10, 2023
Modern Management and Diagnostics in HER2+ Breast Cancer with CNS MetastasisSurbhi Warrior, Adam Cohen-Nowak, Priya Kumthekar
Cancer Medicine|June 23, 2022
Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experienceJessica A Slostad, Nicole K Yun, Aimee E Schad, et al.
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Hematology & Oncology|December 25, 2024
Current and future immunotherapy for breast cancerNatalie K Heater, Surbhi Warrior, Janice Lu
Cancers|June 10, 2023
Modern Management and Diagnostics in HER2+ Breast Cancer with CNS MetastasisSurbhi Warrior, Adam Cohen-Nowak, Priya Kumthekar
Cancer Medicine|June 23, 2022
Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experienceJessica A Slostad, Nicole K Yun, Aimee E Schad, et al.
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.
Pageof 1